REG-Mydecine Innovations Group Inc: Mydecine Announces Filing of Q3 Financial Statements

Mydecine InnovationsAnnouncement

21/11/2024 10:30

MYDECINE ANNOUNCES FILING OF Q3 FINANCIAL STATEMENTS

Vancouver, British Columbia, 21 November 2024 - Mydecine Innovations Group
Inc. (the "Company") (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) is
pleased to confirm that the Company has filed on SEDAR+ its interim Q3
financial statements, accompanying management discussion and analysis and
related CEO and CFO certifications for the nine months ended 30 September 2024
(the "Quarterly Filings"). The Quarterly Filings can be obtained on the
Company's SEDAR+ profile at www.sedarplus.ca.

The Directors of Mydecine take responsibility for this announcement.

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the Company's obligations under Article 17 of
MAR.

On behalf of the Board of Directors,

MYDECINE INNOVATIONS GROUP INC.

Joshua Bartch

Chief Executive Officer

contact@mydecineinc.com

 

AQSE Corporate Advisor

Novum Securities Limited  Tel: +44 (0)207 399 9400

David Coffman/ George Duxberry

 

About Mydecine Innovations Group Inc.

Mydecine Innovations Group™ is a biotechnology company developing the next
generation of innovative medications and therapies to address mental health
disorders such as nicotine addiction and posttraumatic stress disorder (PTSD).
The core strategy blends advanced technology with an elaborate infrastructure
for drug discovery and development. Mydecine's dedicated multinational team
constantly develops new paths for breakthrough treatment solutions in areas
with considerable unmet needs. By collaborating with some of the world's
leading specialists, the Company aspires to responsibly speed up the
development of breakthrough medications to provide patients with safer and
more effective treatment solutions. At the same time, Mydecine's approach
focuses on the next generation of psychedelic medicine by creating innovative
compounds with unmatched therapeutic potential through its clinical trial
efforts with worldclass scientific and regulatory expertise.

Learn more at: https://www.mydecine.com/ and follow the company on Twitter,
LinkedIn, YouTube, and Instagram.

Forward-looking Information Statement

This news release may contain certain "forward-looking statements" and
"forward-looking information" within the meaning of applicable Canadian and
United States securities laws. When used in this news release, the words
"anticipate", "believe", "estimate", "expect", "target, "plan", "forecast",
"may", "schedule" and other similar words or expressions identify
forward-looking statements or information. These forward-looking statements or
information may relate to the anticipated timing for the filing of the Annual
Filings, and other factors or information. Such statements represent the
Company's current views with respect to future events and are necessarily
based upon a number of assumptions and estimates that, while considered
reasonable by the Company, are inherently subject to significant business,
economic, competitive, political and social risks, contingencies and
uncertainties. Many factors, both known and unknown, could cause results,
performance or achievements to be materially different from the results,
performance or achievements that are or may be expressed or implied by such
forward-looking statements. The Company does not intend, and does not assume
any obligation, to update these forward-looking statements or information to
reflect changes in assumptions or changes in circumstances or any other events
affections such statements and information other than as required by
applicable laws, rules and regulations

NEITHER THE CSE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT
RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

 

 4069680_0.png (https://mb.cision.com/Public/22818/4069680/b8aafc3dc49a2be3_org.png)  



Copyright (c) 2024 PR Newswire Association,LLC. All Rights Reserved